Iontas Limited, a biotechnology company focused on antibody discovery and technology development, has entered into a licensing agreement with Bristol Myers Squibb Company regarding the company’s proprietary mammalian display.   Under the terms of this agreement, Iontas will receive an upfront payment for accessing the technology platform and will work with Bristol Myers Squibb in establishing the platform within its facilities. Additional near-term payments include maintenance fees, the achievem...